Generate Biomedicines focuses on AI-enabled drug discovery.

The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen ...

The company is on the verge of becoming a commercial-stage biotech, with two promising therapies in phase 3 trials.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

“You could have the cure for cancer, but if you can’t execute, it doesn’t matter.” ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce ...

Upstream Biotechnology unlocks crops’ own defense systems in response to disease and environmental stress without ...

SAN DIEGO, CA, UNITED STATES, August 4, 2026 /EINPresswire.com/ -- Key Takeaways Investigational New Drug (IND) ...

The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public ...